Future Care Capital launches digital mental health tools
UK charity, Future Care Capital, is launching two new tools to improve access to digital mental health tools and how medical professionals recommend them.
MHRA and NICE receive funding to explore digital mental health tools
MHRA and NICE will be exploring the regulation of digital mental health tools, with help from a £1.8m funding boost from Wellcome.
Industry news in brief
The roundup round-up includes a virtual reality smartphone app for beating phobias and a project which involves AI being used for lung cancer diagnosis.
Trust in AI among healthcare staff and patients ‘will improve with regulation’
AI technology can gain the trust of patients and staff through increased regulation into the technology, a report has stated.
AI and Analytics 5
Assessing the future of regulating the digital health landscape
Andrew Davies, from the Association of British HealthTech Industries, explores what the future regulatory landscape will look like within digital health.
UK medicines watchdog vows to boost interoperability with AI
The MHRA committed to building on established technology platforms to “improve interoperability across the UK health system and internationally”.
NHSX hosts second roundtable discussion on AI regulation in healthcare
A number of key figures, including representatives from NHSX, have met for a roundtable discussion on how to improve AI regulation in healthcare.
AI and Analytics
MHRA seeks input on using EHR data to inform clinical trials
The MHRA is asking stakeholders to help shape new guidance that outlines how greater use of real-world data in clinical trials improve treatments.
AI and Analytics
Health apps developers take note: new MHRA rules are here
As the MHRA expands the range of apps falling under the medical devices regulations, Justyna Ostrowska looks into what developers need to know.
EMIS joins Yellow Card Scheme for reporting adverse drug reactions
The update allows the 4,000 practices using EMIS Web can report to the Yellow Card Scheme, which acts as an early warning for adverse drug reactions.